Theodoros Kelesidis is an Infectious Disease physician affiliated with The University of Texas Southwestern Medical Center. OpenAlex indexes 237 publications with 9,043 citations (h-index 45); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6201 Harry Hines Blvd Dallas
Dallas, TX 753900001
Telephone
214-645-6757Provider last certified this registry record 23 Oct 2023.
Clinical trials
- Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
Sponsor: University of Texas Southwestern Medical Center
- An Open Label Study in Adults to Test the Efficacy of Mitoquinone/Mitoquinol Mesylate to Prevent Severe Viral Illness
Sponsor: University of California, Los Angeles
- Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV
Sponsor: University of Texas Southwestern Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20251 payment
- Merck Sharp & Dohme LLCProgram year20241 payment
- Merck Sharp & Dohme LLCProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 2022–2025 per NIH RePORTER. The latest:
- Mitoquinone/mitoquinol mesylate as oral and safe Postexposure Prophylaxis for Covid-19
Ut Southwestern Medical Center
FY2025$205,000R21AI178632 - Mitoquinone/mitoquinol mesylate as oral and safe Postexposure Prophylaxis for Covid-19
Ut Southwestern Medical Center
FY2023$246,000R21AI178632 - Targeting early instigators of vascular inflammation to prevent and/or delay vascular aging in chronic treated HIV
Ut Southwestern Medical Center
FY2022$335,399R01AG059502
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The role of oxidative stress in the pathogenesis of infections with coronaviruses
Frontiers in Microbiology
2023 - Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s
Clinical Infectious Diseases
2016 - The Role of Platelet-Activating Factor in Chronic Inflammation, Immune Activation, and Comorbidities Associated with HIV Infection.
PubMed
2016
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Toto, MD
The University of Texas Southwestern Medical Center
Margaret Pearle, MD, PhD
The University of Texas Southwestern Medical Center
George Buchanan, MD
The University of Texas Southwestern Medical Center
Vitaly Margulis, MD
The University of Texas Southwestern Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”